Dr Reddy's climbs on US FDA nod for Azacitidine injection
Published: 17th September 2013 01:18 PM
Last Updated: 17th September 2013 01:18 PM
Dr Reddys Laboratories, an integrated
global pharmaceutical company, climbed on Tuesday after it received
US FDA approval for Azacitidine injection 100 mg/vial, a
bioequivalent generic version of Vidaza (azacitidine for injection)
on Sept. 16, 2013.
The Vidaza brand had US sales of approximately USD 378.5 million
for the most recent twelve months ending July 2013 according to IMS
Health. Shares ofthe companyare trading at Rs
2,303.85, up Rs 80.7, or 3.63% at the Bombay Stock Exchange (BSE)
on Tuesday at 12:11 p.m.The scrip has touched an intra-day high of
Rs 2,311.50 and low of Rs 2,220. The total volume of shares traded
at the BSE is 11,779.In the earlier session, the shares declined
1.03%, or Rs 23.25, at Rs 2,223.15. Currently, the stock is trading
down 4.04% from its 52-week high of Rs 2,400.75 and above 42.48%
over the 52-week low of Rs 1,617.
Share Price Movement Period
Pricein Rs Gain/(Loss) in Rs in % 1 Week 2,176.50 (52.70) (2.42) 1
Month 2,051.05 72.75 3.55 3 Months 1,751.95 371.85 21.22 6 Months
1,819.60 304.20 16.72 1 Year 1,581.80 542.00 34.26 Note: Based on
previous day closing price.